文献速递创伤与烧伤复苏、休克与脓毒症

严重创伤院前氨甲环酸治疗

Prehospital Tranexamic Acid for Severe Trauma.
PubMed 文献 · N Engl J Med · 2023-06-14
一句话结论在高级创伤系统中,严重创伤且疑似创伤性凝血病患者院前给予氨甲环酸并未提高6个月良好功能生存率(53.7% vs 53.5%,RR 1.00)。

该随机对照试验纳入澳大利亚、新西兰和德国15个急救医疗服务系统的1310例严重创伤且存在创伤性凝血病风险的成人患者,比较院前静脉推注氨甲环酸1 g后住院后8小时输注1 g与安慰剂的疗效。主要终点6个月良好功能生存率(GOS-E≥5)在氨甲环酸组为53.7%,安慰剂组为53.5%(RR 1.00,95%CI 0.90-1.12,P=0.95),无显著差异。28天全因死亡率氨甲环酸组17.3% vs 安慰剂组21.8%(RR 0.79,95%CI 0.63-0.99),6个月死亡率19.0% vs 22.9%(RR 0.83,95%CI 0.67-1.03)。严重不良事件包括血管闭塞事件两组间无有意义的差异。

要点

  • 在高级创伤系统中,严重创伤且疑似创伤性凝血病患者院前氨甲环酸治疗未提高6个月良好功能生存率(53.7% vs 53.5%,RR 1.00,95%CI 0.90-1.12,P=0.95)。
  • 28天全因死亡率氨甲环酸组17.3% vs 安慰剂组21.8%(RR 0.79,95%CI 0.63-0.99),未达统计学显著。
  • 6个月全因死亡率氨甲环酸组19.0% vs 安慰剂组22.9%(RR 0.83,95%CI 0.67-1.03)。
  • 严重不良事件包括血管闭塞事件两组间无有意义的差异。
  • 氨甲环酸给药方案为院前静脉推注1 g,入院后8小时输注1 g。

适用人群与场景

  • 澳大利亚、新西兰和德国15个急救医疗服务系统收治的严重创伤成人患者。
  • 存在创伤性凝血病风险的患者。

诊断标准与关键阈值

  • 良好功能生存定义为GOS-E评分5分(中度残疾下限)或更高;GOS-E评分范围1分(死亡)至8分(恢复良好)。

处置流程与药物剂量

  • 氨甲环酸组:院前静脉推注1 g,入院后8小时输注1 g。

研究设计与关键结果

  • 多中心随机对照试验,15个急救医疗服务系统,纳入1310例患者,氨甲环酸组661例,安慰剂组646例,3例分组未知。
  • 主要终点:6个月良好功能生存率氨甲环酸组307/572例(53.7%)vs 安慰剂组299/559例(53.5%),RR 1.00(95%CI 0.90-1.12),P=0.95。
  • 28天全因死亡率:氨甲环酸组113/653例(17.3%)vs 安慰剂组139/637例(21.8%),RR 0.79(95%CI 0.63-0.99)。
  • 6个月全因死亡率:氨甲环酸组123/648例(19.0%)vs 安慰剂组144/629例(22.9%),RR 0.83(95%CI 0.67-1.03)。
  • 严重不良事件包括血管闭塞事件两组间无有意义的差异。

证据类型、等级与局限

  • 随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在高级创伤系统中,对严重创伤且疑似创伤性凝血病的成人患者,院前给予氨甲环酸后8小时输注并未较安慰剂提高6个月良好功能生存率。

指南或共识出处

  • PATCH-Trauma试验,ClinicalTrials.gov注册号NCT02187120,由澳大利亚国家健康与医学研究委员会等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Whether prehospital administration of tranexamic acid increases the likelihood of survival with a favorable functional outcome among patients with major trauma and suspected trauma-induced coagulopathy who are being treated in advanced trauma systems is uncertain.

METHODS: We randomly assigned adults with major trauma who were at risk for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus dose of 1 g before hospital admission, followed by a 1-g infusion over a period of 8 hours after arrival at the hospital) or matched placebo. The primary outcome was survival with a favorable functional outcome at 6 months after injury, as assessed with the use of the Glasgow Outcome Scale-Extended (GOS-E). Levels on the GOS-E range from 1 (death) to 8 ("upper good recovery" [no injury-related problems]). We defined survival with a favorable functional outcome as a GOS-E level of 5 ("lower moderate disability") or higher. Secondary outcomes included death from any cause within 28 days and within 6 months after injury.

RESULTS: A total of 1310 patients were recruited by 15 emergency medical services in Australia, New Zealand, and Germany. Of these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned to receive placebo; the trial-group assignment was unknown for 3 patients. Survival with a favorable functional outcome at 6 months occurred in 307 of 572 patients (53.7%) in the tranexamic acid group and in 299 of 559 (53.5%) in the placebo group (risk ratio, 1.00; 95% confidence interval [CI], 0.90 to 1.12; P = 0.95). At 28 days after injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the placebo group had died (risk ratio, 0.79; 95% CI, 0.63 to 0.99). By 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 144 of 629 (22.9%) in the placebo group had died (risk ratio, 0.83; 95% CI, 0.67 to 1.03). The number of serious adverse events, including vascular occlusive events, did not differ meaningfully between the groups.

CONCLUSIONS: Among adults with major trauma and suspected trauma-induced coagulopathy who were being treated in advanced trauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. (Funded by the Australian National Health and Medical Research Council and others; PATCH-Trauma ClinicalTrials.gov number, NCT02187120.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gruen RL, Mitra B, Bernard SA, et al. Prehospital Tranexamic Acid for Severe Trauma. N Engl J Med. 2023. PMID: 37314244. doi:10.1056/NEJMoa2215457

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。